Wegovy gets China approval for liver disease MASH — a first for GLP-1 drugs

Novo Nordisk's blockbuster weight-loss drug Wegovy (semaglutide) has just added another indication to its résumé. China has approved Wegovy as the first GLP-1 receptor agonist (GLP-1 RA) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a serious liver condition closely tied to obesity and metabolic syndrome.

The Danish pharma giant says this approval reflects a growing body of evidence linking Wegovy's benefits to liver health, not just the waistline. The company positioned the approval as a natural extension of Wegovy's established roles in weight management and cardiovascular health, reinforcing its potential as a cornerstone therapy for the broader spectrum of obesity-related complications.

Key Takeaways:

• Wegovy is now the first GLP-1 RA approved in China specifically for MASH treatment
• The approval expands Wegovy's clinical utility across three major domains: weight management, cardiovascular health, and liver health
• MASH is a progressive liver disease with limited treatment options, making this a significant regulatory milestone

Why it matters: MASH affects millions globally and has historically had few approved therapies. Wegovy's China approval signals a meaningful shift in how GLP-1 drugs may be used — not just for weight loss, but as multi-system metabolic disease treatments — with potential implications for regulatory decisions in other markets.